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In this issue of Chemistry & Biology, Blankman et al. [1] identify new enzymes hydrolyzing the
endocannabionoid 2-arachidonoyl glycerol (2-AG), increasing the complexity of endocannabinoid
signaling in the brain, but also pinpointing additional therapeutic targets.The promise of cannabinoid-based
therapies has been gaining momen-
tum for well over a decade. The antic-
ipation has now reached fever pitch
as the first drug targeting the endo-
cannabinoid (eCB) signaling system—
the CB1 receptor antagonist rimona-
bant—has finally reached the public.
An article published by Blankman
et al. [1] in this issue of Chemistry &
Biology extends the exciting possibili-
ties for additional cannabinoid-based
therapeutic interventionswith the iden-
tification of new enzymes belonging
to the eCB signaling system.
The eCB signaling system consists
of the cannabinoid receptors, their
endogenous ligands (the eCBs), and
the metabolic enzymes that control
the availability of those ligands. eCBs
are lipid transmitters that are released
frommembrane precursors by lipases,
activate cannabinoid receptors, and
are then rapidly inactivated by uptake
followed by hydrolysis. The balance
between eCB production and inactiva-
tion determines the extent of eCB
accumulation in tissue and allied can-
nabinoid receptor activation. Changes
in the expression and efficacy of this
signaling system have been implicated
in a wide range of pathophysiological
conditions:
 Cardiovascular/respiratory
disorders - hypertension, asthma
 Pain - acute, chronic
 Inflammation - acute, chronic,
autoimmune
 Energy metabolism disorders -
obesity, anorexiaC Cancer - hematologic, solid
 Gastrointestinal/liver disorders -
diarrhea, fibrosis
 Reproductive abnormalities -
erectile dysfunction, infertility
 Musculoskeletal disorders - ar-
thritis, osteoporosis
 Eye disease - glaucoma, retinop-
athy
 Central nervous system disor-
ders - trauma, stroke, multiple
sclerosis, Parkinson’s disease,
Huntington’s disease, Tourette’s
syndrome, amyotrophic lateral
sclerosis, epilepsy, Alzheimer’s
disease, schizophrenia, anxiety,
depression, insomnia, nausea/
emesis, addiction
The two best-characterized eCBs
are anandamide (AEA) and 2-arachi-
donoyl glycerol (2-AG). The enzyme
involved in AEA hydrolysis, fatty acid
amide hydrolase (FAAH), has been
thoroughly characterized, and its spe-
cific inhibitor, URB597, was shown to
reduce pain, depression, and anxiety
[2, 3], while lacking toxicity and psy-
choactive effects [4]. There is great
hope that additional therapeutics can
be developed by selectively targeting
2-AG hydrolysis in vivo, especially
in light of the fact that 2-AG is a full
and potent agonist at the two principal
cannabinoid receptors (CB1 and CB2)
[5, 6]. Thus, the palpable prediction
is that pharmacological inhibition of
2-AG hydrolysis will provide therapeu-
tic benefit; and monoacylglycerol li-
pase (MGL) emerged as the strongest
candidate for mediating 2-AG hydroly-hemistry & Biology 14, December 2007 ª2sis in vivo. Indeed, administration of
first generation MGL inhibitors leads
to selective 2-AG accumulation in dis-
crete brain regions and mimics stress-
induced analgesia in a rodent model
[7]. However, the molecular mecha-
nism underlying 2-AG hydrolysis ap-
pears more complicated than that for
AEA. Immunodepletion experiments
suggest that MGL accounts for 50%
of the 2-AG hydrolysis activity in brain,
implying the existence of additional
2-AG-hydrolyzing enzymes [8]; accord-
ingly, our lab found thatmicroglial cells,
the main immunocompetant cells of
the brain, hydrolyze 2-AG even in the
absence ofMGL [9]. This exciting reve-
lation has led us to reason that selec-
tive inhibition of a ‘‘novel MGL’’ may
induce distinct cannabimimetic effects
in vivo, including immune regulation.
Members of the Cravatt lab pio-
neered the technique of activity-based
protein profiling (ABPP), which mea-
sures the levels of functionally active
enzymes in tissue by directly probing
active sites. This versatile technique
will likely be instrumental in the char-
acterization and exploitation of a vari-
ety of enzyme classes; fortunately for
us, the eCB field is among the first to
reap its benefits. Using this approach,
Blankman et al. report an exhaustive
analysis of 2-AG hydrolyzing enzymes
in mouse brain, illuminating the physi-
ological relevance of an extensive list
of enzymes that may contribute to
2-AG hydrolysis in vivo. While they
confirm previous results showing that
MGL accounts for 85% of 2-AG hy-
drolase activity in mouse brain, they007 Elsevier Ltd All rights reserved 1309
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Monoacylyglycerol lipase (MGL), ABHD6, and ABHD12 may be located at the plasma membrane,
and at membranes of the nuclei and mitochondria. Cannabinoid receptors (CB1 and CB2) are
abundant at the plasma membrane, while fatty acid amide hydrolase (FAAH) is abundant at the
membrane of the endoplasmic reticulum (ER). The relative importance of MGL, ABHD6, and
ABHD12 in controlling 2-arachidonoyl glycerol (2-AG) levels at these membranes remains to be
determined. Anandamide is not represented in this model, but is likely also an integral constituent
of all these membranes.also identify the previously uncharac-
terized serine hydrolases ABHD6 and
ABHD12 as new players in the eCB
signaling system (one of which is likely
to be the ‘‘novel MGL’’ we have been
seeking in microglial cells).
Perhaps the most intriguing finding
in this report is the observation that
MGL, ABHD6, and ABHD12 have dis-
tinct membrane topologies. MGL is
a cytosolic enzyme that peripherally
associates with membranes, ABHD6
is an integral membrane enzyme with
its active site facing the cytoplasm,
and ABHD12 is an integral membrane
enzyme that faces the luminal/extra-
cellular compartments of the cell.
This important result should be con-
sidered in the context of subcellular
locations, for 2-AG hydrolyzing activi-
ties are expressed not only on plasma
membranes, but also in membranes
of the nucleus and mitochondria [9].
Such subcellular repartition suggests
that unique2-AG-hydrolyzing enzymes
may regulate distinct pools of 2-AG
in intact cells, which should allow for
more specific pharmacological modu-
lations of 2-AG levels (Figure 1).
An important consideration when
targeting ABHD6 and ABHD12 stems1310 Chemistry & Biology 14, Decemberfrom the unconventional nature of
eCB signaling. Unlike classical neuro-
transmitters, bioactive lipids (including
eCBs) tend to be integral mediators
within metabolic sequences of enzy-
matically catalyzed signaling cas-
cades, with each successive molecule
being responsible for a distinctive bio-
logical response, and each enzyme
exhibiting a unique profile of substrate
selectivity. Therefore, inhibiting MGL,
ABHD6, and ABHD12 may have sec-
ondary effects beyond simply increas-
ing 2-AG levels. Such effects are
bound to be different depending on
which 2-AG hydrolyzing enzyme is
inhibited, and targeting one enzyme
may be more beneficial than another.
The potential importance of ABHD6
and ABHD12 compared to the highly
active MGL should not be underesti-
mated, as their respective roles may
differ depending on cell type and
changes in expression due to, for ex-
ample, pathologicalconditions.ABHD6
and ABHD12 will likely prove to be
attractive new therapeutic targets, oc-
cupying unique niches within the eCB
system. In support of such a notion,
we suggest considering the critical im-
portance of the sparse CB1 receptors2007 ª2007 Elsevier Ltd All rights reservedexpressed by glutamatergic neurons,
which surprisingly mediate most of the
psychotropic effects of cannabinoid
compounds, in contrast to the as yet
unclear role of the abundant CB1 re-
ceptors expressed by GABAergic neu-
rons [10]. With 2-AG emerging as the
predominant mediator of eCB-depen-
dent synaptic plasticity [11], pharma-
cological and genetic tools targeting
ABHD6 and ABHD12 will provide neu-
roscientists with valuable new strate-
gies for studying and manipulating
synaptic physiology. This could have
important implications for the fields of
cognition, learning,memory, anddevel-
opment. As our appreciation of the fun-
damental, ubiquitous, and evolution-
arily ancient nature of the eCB system
continues to grow, so too will the list
of disciplines that could benefit from
tools to manipulate 2-AG signaling.
It is gratifying to see that modern
science is now able to exploit the me-
dicinal properties of marijuana (which
people around the world used as med-
icine for thousands of years) by taking
advantage of our newly acquired (and
still emerging) knowledge of itsmecha-
nisms of action. Furthermore, as these
mechanisms continue to reveal them-
selves, it becomes easier to separate
the medicinal benefits from the drug
of abuse aspects that have stigmatized
marijuana. However, our ability to fash-
ion specialized eCB-based therapies
depends on a comprehensive under-
standing of this complicated and per-
vasive signaling system. With their
contribution, Blankman et al. have pro-
vided an integral piece of the puzzle by
identifying two important new players
in this fascinating signaling system.
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‘‘The problem of pain’’ [2] has troubled
everybody, often to the verge of
despair. Equally troublesome and de-
spairing have been efforts at develop-
ing analgesics. Pathwayswere discov-
ered that simply must have something
to do with sensing, transmitting, and
realizing pain, and inhibitors were
found that worked ever so well in the
usual animal models of antinocicep-
tion—but in humans, they apparently
failed to cause or display distinct ef-
fects. In humans at least, pain is
a very subjective state of perception,
and that is probably why linear extrap-
olations from molecular to clinical
effects are rarely possible. Perhaps
the same biochemical events will be
interpreted differently by the mind
when it comes to states of conscious-
ness like pain? To, as it were, chemi-
cally detach a patient from feeling his
pain, without impairing his emotional
and intellectual capacities, remains
a major challenge with very likely no
satisfactory solution.
Listing all known molecular targets
of approved drugs [3], we identified
eight whose stimulation or blockade
are thought to lead to analgesia or anti-
nociception, not counting the targets
of neuroleptics and tranquilizers that7. Hohmann, A.G., Suplita, R.L., Bolton,
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e (MGL). MGL is a hot target for a
ndocannabinoid 2-arachidonoylgly
have an analgetic by-effect. Against
this background, new molecular tar-
gets that hold the promise of being
relevant for nociception are always
welcome. In this context, nociception
or hyperalgesia means that even slight
touches or pressures (e.g., caused
by swellings or inflammation) induce
pain, as opposed to pain caused by
a fracture or hard blow. The endocan-
nabinoid—or rather eicosanoid—sys-
tem that has been discovered during
the past years is strongly involved in
basic sensory physiology including
nociception.
Presently, the endocannabinoid sys-
tem [4, 5] is known to consist mainly of:
(1) two receptors of the G protein cou-
pled receptor family, CB1 and CB2; (2)
endogeneous ligands that are derived
from arachidonic acid, like ananda-
mide and 2-arachidonoyl glycerol
(2-AG); (3) a transporter of anandamide
that has escaped thorough character-
ization so far; and (4) hydrolases that
catalyze the biosynthesis and inactiva-
tion of the ligands. 2-AG is inactivated
by two or more monoacylglycerol
lipases (MGL, MAGL), while ananda-
mide is hydrolyzed by fatty-acid amide
hydrolase (FAAH) and N-acylethanol-
amine acid amidase (NAAA).
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nother interesting paper on inhi-
ntinociceptive agents, being the
cerol [1].
CB receptors are supposed to be
more numerous in the CNS than dopa-
mine receptors, and they were also
found in other body tissues. Endocan-
nabinoid signaling, which is of the
short-range short-term type, is strongly
involved in antinociception, anxiolytic
action, cell proliferation, reproduction,
memory processes, and modulation of
feeding [3].
Due to its abuse, it has long been
known that cannabis has analgesic
effects. At the moment, the following
modulators of the endocannabinoid
system are thought to lead to analge-
sic action: agonists at CB1 and/or
CB2 receptors, inhibitors of FAAH,
and inhibitors of MGL. The latter two
interferences would work indirectly by
increasing the amount of endocanna-
binoids.
Cause-and-effect is anything but
clear with endocannabinoids. Different
literature reports have shown, for in-
stance, the CB2 receptor and 2-AG
to be strongly involved in stimulation
and in attenuation of inflammation
and immune responses [6]. Apart from
the consideration on nondetermined-
ness of psychopharmaceutical ac-
tion, the intertwining of the CB and
other pathways need to be taken
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